- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04205682
Cannabidiol (CBD) for the Treatment of Alcohol Withdrawal
A Randomised Controlled Trial of Cannabidiol (CBD) for the Treatment of Alcohol Withdrawal
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
New treatment strategies for treating symptoms of alcohol dependence are urgently needed. Although alcohol related disorders are a leading cause of preventable death in Australia, their treatment is generally not evidence-based. Contemporary treatment for managing alcohol withdrawal in Australia involves administration of benzodiazepines that, while often effective for managing withdrawal symptoms, have concerns regarding their use including: a major abuse liability potential in this population; their sedating effects and potential for adverse events (e.g. falls, overdose, cognitive impairment) if used in combination with other sedatives; and an increased risk of relapse due to symptoms of alcohol dependence that return after cessation of treatment (e.g. increased sleep problems and anxiety). However, no other safe and effective alternatives to benzodiazepines in treating alcohol withdrawal have yet been demonstrated.
This project will pilot the clinical efficacy and tolerability of Cannabidiol (CBD) relative to placebo in the treatment of alcohol withdrawal in an inpatient setting across two study sites.
This is a double-blind, randomised controlled design. The trial will recruit 52 participants undergoing alcohol withdrawal, using a 1:1 random allocation into one of two treatment groups as follows: (1) CBD (Day 1: 1200 mg/day; Day 2-4: 800 mg/day; Day 5: placebo washout; n = 26), or (2) matched placebo (n = 26). All participants will be administered a symptom triggered diazepam medication regimen, as per conventional best-practice management of alcohol withdrawal.
Study Type
Enrollment (Anticipated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Kirsten Morley, PhD
- Phone Number: +61295153636
- Email: kirsten.morley@sydney.edu.au
Study Locations
-
-
New South Wales
-
Sydney, New South Wales, Australia, 2050
- Royal Prince Alfred Hospital
-
Contact:
- Kirsten Morley, PhD
- Phone Number: +61295153636
- Email: kirsten.morley@sydney.edu.au
-
Principal Investigator:
- Paul Haber, MBBS
-
Sydney, New South Wales, Australia, 2000
- Sydney and Sydney Eye Hospital
-
Contact:
- Nicholas Lintzeris, MBBS
- Email: nicholas.lintzeris@health.nsw.gov.au
-
Principal Investigator:
- Nicholas Lintzeris, MBBS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 18-65 years;
- At least one prior episode 2 days or longer in duration during which the participant experienced withdrawal symptoms that caused significant incapacitation (e.g. inability to work or do normal activities) OR at least one prior inpatient or outpatient medical detoxification during which the participant exhibited withdrawal symptoms of significant magnitude that sedative-hypnotic or anticonvulsant medication was required at least once on 2 consecutive days after cessation of or reduction in the use of alcohol following 2 weeks or more of heavy daily consumption;
- Average consumption of at least 8 standard drinks per day for at least 2 weeks prior to enrolment in the study;
- Adequate cognition and English language skills to give valid consent and complete research interviews;
- Willingness to give written informed consent
Exclusion Criteria:
- Treatment/ingestion during the previous week of benzodiazepines or other sedative-hypnotic medications or history of recent chronic treatment with sedative-hypnotic medication as evidenced by a negative urine drug screen at baseline
- History of alcohol withdrawal related seizures
- Substance use in the previous week, defined as > 3 times per week (not including nicotine or caffeine), inclusive of non-prescribed pharmaceuticals (ATOP to be collected at screening)
- Active major psychiatric disorder associated with psychosis, or significant suicide risk (e.g. Bipolar, Schizophrenia)
- Pregnancy or lactation - Women shall be advised to use reliable contraception for the duration of drug therapy and a urine pregnancy test will be performed where necessary
- History of confirmed seizures during adulthood, and/or current use of anti-epileptic drugs (AED)
- Diagnosis of epilepsy, and/or current use of anti-epileptic drugs (AED)
- Serious medical illness impacting on safety/participation, defined as an unstable medical state in the opinion of the trial medical officer
- Low body weight (body mass index < 17)
- Severe cognitive impairment or insufficient English or literacy to complete study processes
- Concurrent use of drugs potentially exacerbated by CBD via CYP3A5
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cannabidiol (CBD)
Drug: Cannabidiol (day 1: 1200 mg (800 mg BD); day 2-4: 800 mg (400 mg BD); day 5: placebo BD).
|
CBD capsules administered BD for 4-days (800-1200 mg/day), placebo day 5
|
Placebo Comparator: Placebo
Drug: Placebo (days 1-5: placebo matched BD)
|
Placebo capsules administered BD for 5 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diazepam
Time Frame: 5 day admission period
|
Diazepam use over the 5-day withdrawal period (which due to symptom triggered regimen is a proxy measure for withdrawal severity).
Measured by total diazepam use over 5 day period.
|
5 day admission period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Alcohol Withdrawal Severity
Time Frame: 5 day admission period
|
Measured by Alcohol Withdrawal Scale (AWS), minimum score is 0, maximum score is 27 where higher scores indicate greater withdrawal severity.
|
5 day admission period
|
Self-reported Alcohol Withdrawal Severity
Time Frame: 5 day admission period (twice daily)
|
As measured by the Alcohol Withdrawal Severity Checklist (AWSC), a self-report measure of withdrawal severity, minimum score is 0, maximum score is 64 where higher scores indicate greater self-reported withdrawal severity.
|
5 day admission period (twice daily)
|
Self-reported alcohol craving
Time Frame: Baseline, Day 5, and Day 12 and 33 Follow Up
|
As measured by the Penn Alcohol Craving Scale (PACS), minimum score is 0, maximum score is 30 where higher scores indicate greater alcohol craving
|
Baseline, Day 5, and Day 12 and 33 Follow Up
|
Self-reported urges to drink
Time Frame: Twice Daily, days 1-5
|
As measured by the Alcohol Urge Questionnaire (AUQ), minimum score is 8, maximum score is 56, where higher scores indicate greater urges to drink
|
Twice Daily, days 1-5
|
Actiwatch for sleep quality
Time Frame: 5 day admission period
|
as measured using data obtained from the actiwatch worn by participants for duration of inpatient stay
|
5 day admission period
|
Self-reported sleep quality
Time Frame: Baseline, Day 5, and Follow Up (Day 12, Day 33)
|
as measured using the Insomnia Severity Index (ISI), minimum score is 0, maximum score is 28, where higher scores indicate greater insomnia severity.
|
Baseline, Day 5, and Follow Up (Day 12, Day 33)
|
Subjective measure of patient satisfaction
Time Frame: Day 5 and follow up (day 12 and 33)
|
Measured using the Treatment Satisfaction Questionnaire for Medication (TSQM), minimum score is 13, maximum score is 80, where higher scores indicate greater treatment satisfaction.
|
Day 5 and follow up (day 12 and 33)
|
Liver function tests for clinical markers of liver injury
Time Frame: Baseline and follow up (day 12 and 33).
|
as measured by levels of liver enzymes, Alanine Transaminase (ALT), Alkaline Phosphatase (ALP) and Aspartate Transaminase (AST) in blood
|
Baseline and follow up (day 12 and 33).
|
Plasma levels of benzodiazepines
Time Frame: Daily (days 1-5)
|
As measured by concentration of benzodiazepines in blood plasma
|
Daily (days 1-5)
|
Plasma levels of cannabidiol
Time Frame: Daily (days 1-5)
|
As measured by concentration of cannabidiol in blood plasma
|
Daily (days 1-5)
|
Mood
Time Frame: Baseline, day 5 and follow up day 12 and 33.
|
Depression, Anxiety and Stress Symptoms measured by the Depression, Anxiety and Stress Scale (DASS-21), minimum score is 0, maximum score is 63, where higher scores indicate greater levels of depression, anxiety and stress.
|
Baseline, day 5 and follow up day 12 and 33.
|
Cognitive Functioning
Time Frame: Baseline, day 5 and follow up day 12 and 33.
|
As measured by the Montreal Cognitive Assessment (MoCA), maximum score is 30 and where higher scores indicate greater cognitive functioning.
|
Baseline, day 5 and follow up day 12 and 33.
|
Cognitive Functioning
Time Frame: Baseline, day 5 and follow up day 12 and 33.
|
Executive functioning measured by time taken to complete the Trail Making Test A and B (in seconds), where lower scores indicate greater functioning.
|
Baseline, day 5 and follow up day 12 and 33.
|
Comorbid Anxiety Disorders
Time Frame: 4 week follow up (day 33)
|
Assessed using the MINI Neuropsychiatric Interview indicating the presence or absence of anxiety disorders
|
4 week follow up (day 33)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Paul Haber, MBBS, Sydney Local Health District
- Principal Investigator: Nicholas Lintzeris, MBBS, South Eastern Sydney Local Health District
- Principal Investigator: Iain McGregor, PhD, University of Sydney
- Principal Investigator: Kirsten Morley, PhD, University of Sydney
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- X18-0163
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcohol Dependence
-
University Hospital, LilleCompleted
-
Tel-Aviv Sourasky Medical CenterMinistry of Health, IsraelUnknownAlcohol-dependenceIsrael
-
Pop Test Oncology LLCBaylor College of Medicine; Michael E. DeBakey VA Medical Center; Congressionally... and other collaboratorsCompletedPotential Treatment for Alcohol Dependence-Alcohol InteractionUnited States
-
DynamiCare HealthNational Institute on Alcohol Abuse and Alcoholism (NIAAA); RANDActive, not recruitingAlcohol Dependence | Alcohol Use Disorder | Drug DependenceUnited States
-
National Institute on Alcohol Abuse and Alcoholism...CompletedAlcohol Abuse | Alcohol Dependence (Primary Condition)United States
-
University Hospital, Gentofte, CopenhagenCompleted
-
Massachusetts General HospitalCompletedAlcohol Dependence | Drug Abuse | Alcohol Abuse | Drug DependenceUnited States
-
Psychiatric Centre RigshospitaletThe Novavì outpatient clinics, CopenhagenRecruitingAddiction, Alcohol | Alcohol Dependence, in RemissionDenmark
-
University of WashingtonU.S. Army Medical Research and Development CommandCompletedAlcohol Dependence | Substance Abuse | Alcohol Abuse | Substance DependenceUnited States
-
Anders Fink-Jensen, MD, DMSciThe Novavì outpatient clinics, Copenhagen; Neurobiology Research Unit, Rigshospitalet... and other collaboratorsCompletedAddiction, Alcohol | Alcohol Dependence, in RemissionDenmark
Clinical Trials on Cannabidiol
-
Marius HenriksenCompleted
-
University of Colorado, BoulderNot yet recruitingDepression | Pain | Sleep | AnxietyUnited States
-
University of Colorado, BoulderNot yet recruiting
-
University of Colorado, BoulderNational Institute on Drug Abuse (NIDA)Not yet recruitingCannabis Use Disorder
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)RecruitingTobacco Use | Tobacco Smoking | Tobacco Use Disorder | Tobacco Use Cessation | Tobacco DependenceUnited States
-
Zynerba Pharmaceuticals, Inc.Enrolling by invitationFragile X SyndromeUnited States, United Kingdom, New Zealand, Australia
-
Elena PopeAvicanna IncWithdrawnPain | Epidermolysis Bullosa | ItchCanada
-
University of Mississippi, OxfordUnknown
-
Yale UniversityNational Institute on Drug Abuse (NIDA); VA Connecticut Healthcare SystemRecruiting
-
University of Northern ColoradoCompleted